Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: An effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?

BJU International

Volumn 104, Issue 5, 2009, Pages 633-639

  Damiano, Rocco ^a   De Sio, Marco ^a   Quarto, Giuseppe ^a   Di Lorenzo, Giuseppe ^a   Perdonà, Sisto ^a   Palumbo, Italo M ^a   Azzarito, Giuseppina ^a   Giugliano, Francesco ^a   Autorino, Riccardo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Intravesical therapy; Prulifloxacin; Side effects

Indexed keywords

BCG VACCINE; CEPHALOSPORIN; EPIRUBICIN; ISONIAZID; MITOMYCIN C; OFLOXACIN; PRULIFLOXACIN; TUBERCULOSTATIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTHRALGIA; ARTHRITIS; ARTICLE; BLADDER CANCER; BLADDER CONTRACTION; CANCER INVASION; CANCER PATIENT; CANCER RISK; CHILL; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPLIANCE (PHYSICAL); CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; CYSTOSCOPY; DRUG CAPSULE; DRUG EFFECT; DRUG INSTILLATION; DRUG WITHDRAWAL; EPIDIDYMITIS; FEMALE; FEVER; HEMATURIA; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; LUNG INFECTION; MALAISE; MALE; MORBIDITY; OPEN STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; SEPSIS; SIDE EFFECT; SYMPTOM; TERTIARY HEALTH CARE; TOXICITY; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; URETER OBSTRUCTION;

ADMINISTRATION, INTRAVESICAL; ANTI-BACTERIAL AGENTS; BCG VACCINE; DIOXOLANES; DRUG THERAPY, COMBINATION; DRUG TOXICITY; EPIDEMIOLOGIC METHODS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PIPERAZINES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 68849094563     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08469.x     Document Type: Article

References (35)

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008 54 : 303 14
2. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976 116 : 180 3
3. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006 67 : 1216 23
4. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer (a meta-analysis of randomized trials). BJU Int 2004 93 : 485 90
5. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published Results of randomized clinical trials. J Urol 2002 168 : 1964 70
6. Böhle A, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004 63 : 682 7
7. Zlotta AR, van Vooren JP, Huygen K et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000 37 : 470 7
8. Van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003 44 : 429 34
9. Rischmann P. Improving compliance of BCG immunotherapy: practical approaches to managing side-effects. Eur Urol Suppl 2006 5 : 660 2
10. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006 176 : 935 9
11. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004 64 : 2221 36
12. Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int 2005 74 : 326 31
13. Saint F, Irani J, Patard JJ et al. Tolerability of bacilli Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 2001 57 : 883 8
14. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006 49 : 466 77
15. Martínez-Piñeiro JA, Flores N, Isorna S et al. for CUETO (Club Urológico Español de Tratamiento Oncológico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002 89 : 671 80
16. Ojea A, Nogueira JL, Solsona E et al. for the CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007 52 : 1398 406
17. Agrawal MS, Agrawal M, Bansal S, Agarwal M, Lavania P, Goyal J. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma. Urology 2007 70 : 1075 8
18. Urdaneta G, Solsona E, Palou J. Intravesical chemotherapy and BCG for the treatment of bladder cancer: evidence and opinion. Eur Urol Suppl 2008 7 : 542 7
19. Andius P, Fehrling M, Holmang S. Intravesical bacillus Calmette-Guérin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 2005 96 : 1290 3
20. Bassi P, Spinadin R, Carando R, Balta G, Pagano F. Modified induction course: a solution to side-effects? Eur Urol 2000 37 (Suppl. 1) : 31 2
21. van der Meijden AP, Brausi M, Zambon V et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 2001 166 : 476 81
22. Al Khalifa M, Elfving P, Månsson W et al. The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer. Eur Urol 2000 37 (Suppl. 1) : 26 30
23. Lockyer CR, Sedgwick JE, Gillatt DA. Beware the BCG failures: a review of one institution's Results. Eur Urol 2002 42 : 542 6
24. Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002 167 : 2408 12
25. Witjes JA, Palou J, Soloway M et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 2008 7 : 667 74
26. Durek C, Jurczok A, Werner H, Jocham D, Bohle A. Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model. J Urol 2002 168 : 826 31
27. Prats G, Rossi V, Salvatori E, Mirelis B. Prulifoxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther 2006 4 : 27 41
28. Giannarini G, Mogorovich A, Valent F et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J Chemother 2007 19 : 304 8
29. Mari M. [Single dose versus 5-day course of oral prulifloxacin in antimicrobial prophylaxis for transrectal prostate biopsy]. Minerva Urol Nefrol 2007 59 : 1 10
30. Prezioso D, Bartoletti R, Damiano R, Morgia G. [Antibacterial prophylaxis in endourological procedures]. Minerva Urol Nefrol 2006 58 : 73 80
31. O'Donnell M. Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer? Nat Clin Pract Urol 2007 4 : 304 5
32. Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008 53 : 992 1001
33. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol 2003 169 : 1706 8
34. Kamat AM, Lamm DL. Antitumor activity of common antibiotics against superficial bladder cancer. Urology 2004 63 : 457 60
35. Matera MG. Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 2006 19 (Suppl. 1 20 9